Literature DB >> 32134429

Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes.

Benoît Rousseau1, Joana Vidal1,2, Luis A Diaz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32134429     DOI： 10.1001/jamaoncol.2020.0065

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  2 in total

1.  Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor.

Authors:  Junjun He; Wei Ouyang; Wugan Zhao; Lin Shao; Bing Li; Bihao Liu; Dejuan Wang; Han Han-Zhang; Zhou Zhang; Liang Shao; Wencai Li
Journal:  Ann Transl Med       Date:  2021-01

2.  High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE-hypermutated colorectal cancers.

Authors:  Loetitia Favre; Justine Cohen; Julien Calderaro; Adrien Pécriaux; Cong-Trung Nguyen; Rémi Bourgoin; Laura Larnaudie; Aurélie Dupuy; Marie Ollier; Emmanuèle Lechapt; Ivan Sloma; Christophe Tournigand; Benoit Rousseau; Anaïs Pujals
Journal:  Mol Oncol       Date:  2022-07-14       Impact factor: 7.449
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.